Navigation Links
Watson and Actavis Receive FTC Second Request
Date:7/12/2012

PARSIPPANY, N.J., July 12, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Watson's pending acquisition of Actavis Group.  The information request was issued under notification requirements of the Hart.Scott Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act").  The effect of the second request is to extend the waiting period imposed by the HSR Act until 30 days after Watson and Actavis have substantially complied with the request, unless that period is extended voluntarily by the parties or terminated sooner by the FTC.  Watson intends to cooperate fully with the FTC's review and continues to expect the transaction to close in the fourth quarter of 2012.

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement
Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; the receipt of required regulatory approvals for the Actavis acquisition transaction (including the approval of antitrust authorities necessary to complete the acquisition);  and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and Watson's Annual Report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. CONTACTS: Investors:Lisa DeFrancesco (862) 261-7152Media:Charlie Mayr (862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
2. Watson to Acquire Actavis Group for EUR4.25 Billion
3. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
4. Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
5. Watson Confirms Lo Loestrin® Fe Patent Challenge
6. Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
7. Watson Confirms Testim® Patent Challenge
8. Watson to Present at the Jefferies 2012 Global Healthcare Conference
9. Watson Announces Lidoderm® Patent Challenge Settlement
10. Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm®
11. Watson to Host Second Quarter 2012 Earnings Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... The Institute for In Vitro Sciences (IIVS), ... of a VITROCELL® inhalation exposure system thanks to a ... device, which is designed to replace animals in inhalation ... to airborne test materials in an environment that mimics ... for testing combustible tobacco products, as well as next ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston ... and unparalleled access to global decision makers and innovative ... 800+ life science leaders during two impactful days. BioPharm ... provides delegates with additional networking opportunities with 4,500+ life ...
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of Diplomat ... families to thrive on nutrition support. To celebrate its anniversary, ... site has a fresh new look with improved organization to create the ... ... "We,ve ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... July 26, 2017 , ... ... Engineering (ISPE) will host its 2017 Process Validation and Process Validation ... offer comprehensive solutions to process validation lifecycle challenges faced by process validation ...
(Date:7/26/2017)... ... 2017 , ... A global center of excellence specializing in ... of the art center will provide advanced surgical care (heart surgery), management of ... patients longer lives. , North American Veterinary Heart Center, the “Heart Center,” will ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... innovative specialty pharmacies, has released an updated version of the HCV Treatment Path ... for treating chronic hepatitis C virus (HCV) infection. All of the latest HCV ...
(Date:7/25/2017)... ... 25, 2017 , ... Creative Pharmacist and ... the Pharmacist eCare Plan to Computer-Rx pharmacies through the STRAND platform. ... to develop the Pharmacist eCare Plan, a shared document detailing a patient’s current ...
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Gina Negrette, a ... more than a decade of experience in psychiatry, treating clients in diverse settings, ... eating disorders, psychotic and manic conditions, as well as those who were fighting ...
Breaking Medicine News(10 mins):